What the FDA labels say about taking them together
Atazanavir and lurasidone
Atazanavir's FDA label of August 6, 2025 names lurasidone in its contraindications section, and lurasidone's label names atazanavir too. The lurasidone label: “Concomitant use of LATUDA with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the lurasidone FDA label on DailyMed (effective January 31, 2025, Sumitomo Pharma America, Inc.).
What does the atazanavir label say about lurasidone?
Atazanavir label, contraindicationsDrug Class: Antipsychotics; Drugs within class that are contraindicated with atazanavir capsules: Lurasidone (with ritonavir), pimozide
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: lurasidone quetiapine; Effect on Concentration of Atazanavir or Concomitant Drug: Atazanavir with ritonavir ↑ lurasidone Atazanavir ↑ lurasidone ↑ quetiapine; Clinical Comment: Atazanavir with ritonavir Coadministration of lurasidone with atazanavir with ritonavir is contraindicated. This is due to the potential for serious and/or life-threatening reactions [see ]. Atazanavir without ritonavir If coadministration is necessary, reduce the lurasidone dose. Refer to the lurasidone prescribing information for concomitant use with moderate CYP3A4 inhibitors. …
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the lurasidone label say about atazanavir?
Lurasidone label, drug interactionsModerate CYP3A4 Inhibitors Clinical Impact: Concomitant use of LATUDA with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone. Intervention: LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 [see Dosage and Administration ()]. Examples: Diltiazem, atazanavir, erythromycin, fluconazole, verapamil
Source: FDA drug label (Latuda), NDA200603 (Sunovion Pharms Inc), as published by Sumitomo Pharma America, Inc., effective January 31, 2025 (SPL set afad3051-9df2-4c54-9684-e8262a133af8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Lurasidone | |
|---|---|---|
| Labeled for | HIV | Schizophrenia, Bipolar disorder, Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.142 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once